EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure

Paul S Pagel, Dustin Hang, Julie K Freed, George J Crystal

Journal of Cardiothoracic and Vascular Anesthesia · 2026

DOI: 10.1053/j.jvca.2026.02.035 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2026. Verfasst von Paul S Pagel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: pspagel@mcw.edu. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Heart Failure, Soluble Guanylyl Cyclase, Guanylate Cyclase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 226 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway is a major regulator of cardiovascular and renal homeostasis that causes vasodilation and protects against maladaptive remodeling. Abnormal NO-sGC-cGMP signaling, characterized by decreases in NO synthesis, sGC activation, and cGMP formation, has been shown to play an essential role in the pathogenesis of 2 major phenotypes of pulmonary hypertension and in the development of heart failure. A new class of medications, known as sGC stimulators, circumvents the reduction in NO availability by binding directly to sGC and catalyzing the formation of cGMP independent of NO. The sGC stimulators also synergistically enhance the enzyme's activity when NO is bound. These actions increase cGMP production in vascular smooth muscle and myocardium, restoring the endogenous protective effects of the cascade. This article first briefly reviews the normal physiology of NO-sGC-cGMP signaling and discusses its pathophysiological implications. It then describes the development and biochemistry of sGC stimulators, including riociguat and vericiguat, their mechanism of action, and the pharmacologic rationale for their use in pulmonary hypertension and heart failure. It subsequently examines the clinical evidence supporting the use of these drugs in patients with chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension, and heart failure with reduced ejection fraction. Finally, the article comments on their potential anesthetic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryHeart FailureSoluble Guanylyl CyclaseGuanylate CyclaseReceptors, Cytoplasmic and NuclearCardiovascular AgentsHumansAnimalsEnzyme ActivatorsPyrazolesPyrimidinesCyclic GMP

Stichwörter der Autor:innen

HFrEFcGMPchronic thromboembolic pulmonary hypertensionnitric oxidepulmonary arterial hypertensionriociguatsoluble guanylate cyclasevericiguat

Substanzen

Soluble Guanylyl CyclaseGuanylate CyclaseReceptors, Cytoplasmic and NuclearEnzyme ActivatorsriociguatPyrazolesPyrimidinesCyclic GMPCardiovascular Agents

Autor:innen und Institutionen

  • Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI. Electronic address: pspagel@mcw.edu.
  • Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI.
  • Department of Anesthesiology, University of Illinois College of Medicine, Chicago, IL.

Zitieren

APA

Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026). Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure. Journal of Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1053/j.jvca.2026.02.035

Vancouver

Pagel PS, Hang D, Freed JK, Crystal GJ. Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure. Journal of Cardiothoracic and Vascular Anesthesia. 2026. doi:10.1053/j.jvca.2026.02.035

BibTeX
@article{Pagel2026,
  author = {Pagel, Paul S and Hang, Dustin and Freed, Julie K and Crystal, George J},
  title = {Advances in Cardiovascular Pharmacotherapy: VII. Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension and Heart Failure},
  journal = {Journal of Cardiothoracic and Vascular Anesthesia},
  year = {2026},
  doi = {10.1053/j.jvca.2026.02.035}
}
Kostenlos starten →